On November 3, 2021, GRO Biosciences Inc. (GRObio), an emerging biotechnology company leveraging groundbreaking science to expand the amino acid alphabet and deliver on the promise of protein therapeutics, announced the closing of a Series A financing totaling $25 million, co-led by Leaps by Bayer and Redmile Group. The financing was joined by lead seed investors Digitalis Ventures, Innovation Endeavors, and others, bringing the total investment to $31.2 million.

GRObio’s mission is to transform protein-based therapies for increasingly prevalent chronic medical conditions including autoimmune and metabolic diseases. The capital raised will support development of the GRO platform, scale-up of bioprocess manufacturing, preclinical validation studies, and IND-enabling studies for GRObio’s pipeline of unique non-standard amino acid (NSAA) protein therapeutics to treat autoimmune and metabolic diseases.

Wilson Sonsini Goodrich & Rosati advised GRObio on intellectual property and technology transactions matters related to the financing. The team includes Chris McAndrew, Lou Lieto, and Farah Gerdes.

For more information, please see GRObio’s press release.